By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
It seems hard to believe that Life Science Leader’s (LSL) first annual outlook issue was published more than two U.S. Presidents ago. Back then, I noted futurist Ray Kurzweil’s prediction that within the next 10 years 3D printers would be able to print an inexhaustible supply of human organs — free from rejection issues. I also referenced how industry outsiders were keen to disrupt life sciences. But perhaps the most profound statement shared within that editor’s note came from a little-known industry insider, Hal Gunn, M.D. During a telephone call, the CEO of Qu Biologics (a company he cofounded in 2007) stated, “Opportunity in biopharma lies in doing things outside the way they are commonly done.” As evidenced by the unprecedented development and distribution of mRNA COVID-19 vaccines, it seems no truer words were ever spoken. Time remains to see if Kurzweil’s prediction proves prophetic. While I still believe there remain important roles for industry outsiders to play in helping industry insiders see things differently, I predict the role played by the next generation of industry insiders will be what will forever change biopharma for the better. And, as a group that grew up fluent in social media, I anticipate an exponential sharing of ideas that further accelerates innovation across all disciplines.